PTPRS

Receptor-type tyrosine-protein phosphatase S · Q13332 · PTPRS on Sugi Atlas →

1,521 patent compounds predicted against PTPRS, 1,251 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL10243369	1.00	8/20
SCHEMBL11662442	0.74	8/20
SCHEMBL10243372	0.73	8/20
SCHEMBL3860743	0.55	7/20
SCHEMBL1975654	0.53	7/20
SCHEMBL1977221	0.53	7/20
Baicalein (SCHEMBL139617)	1.00	6/20
Baicalein (SCHEMBL5695785)	1.00	6/20
Baicalein (SCHEMBL2420136)	0.97	6/20
Baicalein (SCHEMBL11094929)	0.84	6/20
SCHEMBL3859265	0.78	6/20
SCHEMBL5163483	0.71	6/20
SCHEMBL3190273	0.44	6/20
SCHEMBL8137218	0.38	6/20
Scutellarein (SCHEMBL142093)	1.00	5/20
Scutellarein (SCHEMBL1900314)	0.97	5/20
Scutellarein (SCHEMBL15090395)	0.97	5/20
Scutellarein (SCHEMBL15241295)	0.97	5/20
SCHEMBL8250407	0.94	5/20
Baicalein (SCHEMBL3430203)	0.78	5/20

Clinical trials — most relevant to PTPRS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
New Individualized Therapy Trial for Metastatic Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases	nan	NOT_YET_RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPRS binder may also engage these)

Protein	Name	Similarity
Q64605	—	1.000	Q64605 →
B0V2N1	—	0.999	B0V2N1 →
A7MBJ4	—	0.999	A7MBJ4 →
Q64604	—	0.999	Q64604 →
PTPRF	Receptor-type tyrosine-protein phosphatase F	0.995	landscape →
A2A8L5	—	0.994	A2A8L5 →
A4IFW2	—	0.989	A4IFW2 →
P23468	—	0.989	P23468 →
Q64487	—	0.988	Q64487 →
Q3UH53	—	0.987	Q3UH53 →
O94856	—	0.986	O94856 →
Q8AV58	—	0.986	Q8AV58 →
F1NWE3	—	0.984	F1NWE3 →
Q7Z5N4	—	0.984	Q7Z5N4 →
O97394	—	0.983	O97394 →
P16621	—	0.981	P16621 →
Q9EQS9	—	0.981	Q9EQS9 →
Q2VWP9	—	0.981	Q2VWP9 →
Q8TDY8	—	0.980	Q8TDY8 →
Q2EY15	—	0.979	Q2EY15 →
Q2VWP7	—	0.979	Q2VWP7 →
Q9QZS7	—	0.979	Q9QZS7 →
G5EF96	—	0.979	G5EF96 →
Q6V4S5	—	0.978	Q6V4S5 →
Q589G5	—	0.978	Q589G5 →
Q02246	—	0.978	Q02246 →
Q05695	—	0.978	Q05695 →
O42414	—	0.977	O42414 →
Q90478	—	0.977	Q90478 →
O55005	—	0.977	O55005 →